You are here

  • Home
  • Archive
  • Volume 32, Issue Suppl 2
  • 2022-RA-708-ESGO Real-world assessment of patients with ovarian cancer who received niraparib as second-line maintenance therapy in the United States: did first-line maintenance approval change the patient profile for second-line maintenance therapy?

Article metrics

Article menu

Download PDFPDF

Ovarian cancer
2022-RA-708-ESGO Real-world assessment of patients with ovarian cancer who received niraparib as second-line maintenance therapy in the United States: did first-line maintenance approval change the patient profile for second-line maintenance therapy?
Free

 

Online download statistics by month:

Online download statistics by month: October 2022 to October 2024

AbstractFullPdf
Oct 20221602
Nov 202222010
Dec 202262012
Jan 20234006
Feb 202321010
Mar 202319011
Apr 20232604
May 20231002
Jun 2023403
Jul 20231403
Aug 20231004
Sep 2023503
Oct 20231105
Nov 20231403
Dec 2023904
Jan 20242201
Feb 20241001
Mar 202415019
Apr 2024905
May 2024600
Jun 20242502
Jul 2024502
Aug 2024904
Sep 2024904
Oct 2024800
Total4010120